Coexisting opportunities and challenges: In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer?

Curative therapy was not previously available for patients with advanced non-small cell lung cancer (NSCLC); thus, the concept of minimal/measurable (or molecular) residual disease (MRD) was not applicable to these patients. However, advances in targeted and immunotherapy have revolutionized the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Hanfei, Li, Wenqian, Wang, Bin, Chen, Neifei, Qian, Lei, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580798/
https://www.ncbi.nlm.nih.gov/pubmed/34815631
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.05.04

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580798/
https://www.ncbi.nlm.nih.gov/pubmed/34815631
http://dx.doi.org/10.21147/j.issn.1000-9604.2021.05.04

Ejemplares similares